CompletedNCT04641143
Efficacy and Safety Study of Adjunctive Troriluzole in OCD
Official study title
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Chandler, United States · Phoenix, United States and 63 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: December 22, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 456
- Sponsor
- Biohaven Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04641143
Recruitment & locations
CompletedChandler · Phoenix · Bellflower
62 more locations
- Colton
- Encino
- Glendale
- Los Alamitos
- Los Angeles
- Oceanside
- Orange
- Redlands
- San Jose
- Sherman Oaks
- Stanford
- Torrance
- New Haven
- Norwich
- Boca Raton
- Coral Gables
- Hialeah
- Lakeland
- Lauderhill
- Miami
- Miami Springs
- North Miami
- Orange City
- Orlando
- Pembroke Pines
- Tampa
- Weston
- Winter Park
- Decatur
- Savannah
- Boise
- Chicago
- Elgin
- Naperville
- Overland Park
- Gaithersburg
- Pikesville
- Boston
- Methuen
- Springfield
- Ann Arbor
- Flowood
- O'Fallon
- Las Vegas
- Berlin
- Toms River
- Brooklyn
- Cedarhurst
- Great Neck
- Mount Kisco
- New York
- Staten Island
- Beavercreek
- Tulsa
- Media
- Providence
- Austin
- Dallas
- Fort Worth
- Houston
- Missouri City
- Bellevue
Questions about this study
Who is behind this study?
The study sponsor is Biohaven Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including Troriluzole and Placebo.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01404208
2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD
United States
CompletedNCT05624528
A study of Tolcapone in OCD
United States
CompletedNCT01674361
Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in people with OCD (OCD)
United States, Canada